PLASMA-LYTE R IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PLASMA-LYTE R IN PLASTIC CONTAINER (PLASMA-LYTE R IN PLASTIC CONTAINER).
Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.
| Metabolism | Not metabolized; acetate and gluconate are metabolized to bicarbonate in the liver and peripheral tissues. |
| Excretion | Renal: >90% (electrolytes and water); Biliary/fecal: negligible (<5%) |
| Half-life | Not applicable (Plasma-Lyte R components are endogenous electrolytes and water; administered crystalloid redistributes rapidly; half-life of approximately 20-30 minutes for volume expansion due to renal excretion and redistribution into interstitial space) |
| Protein binding | Minimal (<5%); ions remain free in solution |
| Volume of Distribution | Approximately 0.25-0.3 L/kg (limited to extracellular fluid compartment; distributes primarily in plasma and interstitial fluid) |
| Bioavailability | Intravenous: 100% |
| Onset of Action | Intravenous: Immediate (within seconds) for electrolyte and volume effects |
| Duration of Action | Intravenous: 1-2 hours for volume expansion (depending on renal function and hydration status); electrolyte effects persist until renal excretion |
Intravenous infusion at a rate of 25-50 mL/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (creatinine clearance < 30 mL/min) due to risk of hyperkalemia and fluid overload. For mild-to-moderate impairment (CrCl 30-89 mL/min), reduce infusion rate by 25-50% and monitor serum potassium. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh B: Reduce infusion rate by 25% and monitor for fluid overload. Child-Pugh C: Avoid use due to risk of exacerbating ascites and electrolyte imbalances. |
| Pediatric use | Weight-based dosing: 20-100 mL/kg/day as a continuous infusion, with rate not exceeding 50 mL/kg/hour. Adjust based on hydration status, serum electrolytes, and renal function. |
| Geriatric use | Initiate at low end of dosing range (e.g., 25-30 mL/kg/day) due to age-related renal decline and increased risk of fluid overload. Monitor serum potassium, creatinine, and fluid balance closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PLASMA-LYTE R IN PLASTIC CONTAINER (PLASMA-LYTE R IN PLASTIC CONTAINER).
| Breastfeeding | Compatible with breastfeeding. The components are normal blood constituents; no excretion into milk expected. M/P ratio not applicable; no risk to nursing infant. |
| Teratogenic Risk | No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No fetal risk identified in any trimester when used as indicated. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypernatremia","Hyperchloremia","Metabolic alkalosis","Severe renal impairment with oliguria","Hypersensitivity to any component"]
| Precautions | ["Use with caution in patients with heart failure, renal impairment, or conditions with sodium retention","Monitor serum electrolytes and fluid balance","Risk of hypervolemia","Do not use if solution contains precipitate or if container is damaged"] |
Loading safety data…
| Monitor maternal serum electrolytes, fluid balance, and renal function during prolonged infusion. Fetal heart rate monitoring not specifically required unless maternal condition warrants. |
| Fertility Effects | No known adverse effects on fertility. Components are physiological and do not impair reproductive function. |